BACKGROUND: The National HIV/AIDS Strategy proposes to scale-up post-exposure prophylaxis (PEP). Intensive risk reduction and adherence counseling appear to be effective but are resource intensive. Identifying simpler interventions that maximize the HIV prevention potential of PEP is critical. METHODS: A randomized noninferiority study comparing 2 (standard) or 5 (enhanced) risk reduction counseling sessions was performed. Adherence counseling was provided in the enhanced arm. We measured changes in unprotected sexual intercourse acts at 12 months, compared with baseline; HIV acquisition; and PEP adherence. Outcomes were stratified by degree of baseline risk. RESULTS: We enrolled 457 individuals reporting unprotected intercourse within 72 h with an HIV-infected or at-risk partner. Participants were 96% male and 71% white. There were 1.8 and 2.3 fewer unprotected sex acts in the standard and enhanced groups. The maximum potential risk difference, reflected by the upper bound of the 95% confidence interval, was 3.9 acts. The difference in the riskier subset may have been as many as 19.6 acts. The incidence of HIV seroconversion was 2.9% and 2.6% among persons randomized to standard and enhanced counseling, respectively, with a maximum potential difference of 3.4%. The absolute and maximal HIV seroconversion incidence was 9.9% and 20.4% greater in the riskier group randomized to standard, compared with enhanced, counseling. Adherence outcomes were similar, with noninferiority in the lower risk group and concerning differences among the higher-risk group. CONCLUSIONS: Risk assessment is critical at PEP initiation. Standard counseling is only noninferior for individuals with lower baseline risk; thus, enhanced counseling should be targeted to individuals at higher risk.
RCT Entities:
BACKGROUND: The National HIV/AIDS Strategy proposes to scale-up post-exposure prophylaxis (PEP). Intensive risk reduction and adherence counseling appear to be effective but are resource intensive. Identifying simpler interventions that maximize the HIV prevention potential of PEP is critical. METHODS: A randomized noninferiority study comparing 2 (standard) or 5 (enhanced) risk reduction counseling sessions was performed. Adherence counseling was provided in the enhanced arm. We measured changes in unprotected sexual intercourse acts at 12 months, compared with baseline; HIV acquisition; and PEP adherence. Outcomes were stratified by degree of baseline risk. RESULTS: We enrolled 457 individuals reporting unprotected intercourse within 72 h with an HIV-infected or at-risk partner. Participants were 96% male and 71% white. There were 1.8 and 2.3 fewer unprotected sex acts in the standard and enhanced groups. The maximum potential risk difference, reflected by the upper bound of the 95% confidence interval, was 3.9 acts. The difference in the riskier subset may have been as many as 19.6 acts. The incidence of HIV seroconversion was 2.9% and 2.6% among persons randomized to standard and enhanced counseling, respectively, with a maximum potential difference of 3.4%. The absolute and maximal HIV seroconversion incidence was 9.9% and 20.4% greater in the riskier group randomized to standard, compared with enhanced, counseling. Adherence outcomes were similar, with noninferiority in the lower risk group and concerning differences among the higher-risk group. CONCLUSIONS: Risk assessment is critical at PEP initiation. Standard counseling is only noninferior for individuals with lower baseline risk; thus, enhanced counseling should be targeted to individuals at higher risk.
Authors: Gerard J B Sonder; Jan M Prins; Rosa M Regez; Kees Brinkman; Jan-Willem Mulder; Jan Veenstra; Frans A P Claessen; Anneke van den Hoek Journal: Sex Transm Dis Date: 2010-11 Impact factor: 2.830
Authors: Suzanne Lunding; Terese L Katzenstein; Gitte Kronborg; Jens A Lindberg; Janne Jensen; Henrik I Nielsen; Court Pedersen; Louise B Jørgensen Journal: Sex Transm Dis Date: 2010-01 Impact factor: 2.830
Authors: J O Kahn; J N Martin; M E Roland; J D Bamberger; M Chesney; D Chambers; K Franses; T J Coates; M H Katz Journal: J Infect Dis Date: 2001-02-01 Impact factor: 5.226
Authors: Jeffrey N Martin; Michelle E Roland; Torsten B Neilands; Melissa R Krone; Joshua D Bamberger; Robert P Kohn; Margaret A Chesney; Karena Franses; James O Kahn; Thomas J Coates; Mitchell H Katz Journal: AIDS Date: 2004-03-26 Impact factor: 4.177
Authors: Steven D Pinkerton; Jeffrey N Martin; Michelle E Roland; Mitchell H Katz; Thomas J Coates; James O Kahn Journal: Arch Intern Med Date: 2004-01-12
Authors: Mauro Schechter; Regina F do Lago; Aaron B Mendelsohn; Ronaldo I Moreira; Lawrence H Moulton; Lee H Harrison Journal: J Acquir Immune Defic Syndr Date: 2004-04-15 Impact factor: 3.731
Authors: Margaret A Chesney; Donald B Chambers; Jonelle M Taylor; Lisa M Johnson; Susan Folkman Journal: Psychosom Med Date: 2003 Nov-Dec Impact factor: 4.312
Authors: J L Marcus; T Buisker; T Horvath; K R Amico; J D Fuchs; S P Buchbinder; R M Grant; A Y Liu Journal: HIV Med Date: 2014-02-24 Impact factor: 3.180
Authors: Connie Celum; Jared M Baeten; James P Hughes; Ruanne Barnabas; Albert Liu; Heidi Van Rooyen; Susan Buchbinder Journal: J Acquir Immune Defic Syndr Date: 2013-07 Impact factor: 3.731